Tag: nuclear imaging tests for neuroendocrine tumor patients
Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients
For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in the United States, Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, in collaboration with…
READ MORE
OncLive TV Releases 2 More Videos in Neuroendocrine Tumors Series
Two new videos have been released in the OncLive TV series on carcinoid and neuroendocrine tumors (NETs), including pancreatic neuroendocrine tumors, and genetic syndromes that predispose people to develop pancreatic NETs such MEN1 (multiple endocrine…
READ MORE
California Carcinoid and Neuroendocrine Tumor Conference Scheduled for January
Carcinoid and neuroendocrine tumor patients and their families are invited to attend the 2012 NET Patient Half Day Conference on Sunday, January 22 in San Francisco, California. The latest developments in NET cancers, including clinical trials, …
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MORE
